Prospective Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in France (TARANIS)

First published 15/11/2016

Last updated 22/02/2024

EU PAS number:

EUPAS16212

Study

Finalised

Documents

Study protocol

Initial protocol

protocol GS-FR-292-4043 original 26092016 final

English (1.23 MB - PDF)View document

Updated protocol

GS-FR-292-4043-appendix-16.1.1-protocol amendment 2_f-redact

First published: 22/02/2024

English (3.58 MB - PDF)View document

Study results

GS-FR-292-4043-csr-final-abstract_f-redact

English (904.52 KB - PDF)View document

Study report

Other information

Secondary tabs